Hani Gabra
Gründer bei Papyrus Therapeutics, Inc.
Aktive Positionen von Hani Gabra
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Imperial College London | Corporate Officer/Principal | - | - |
Papyrus Therapeutics, Inc.
 Papyrus Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Papyrus Therapeutics, Inc. is a preclinical stage biopharma American company that focuses on developing cancer therapeutics based on a novel target, opioid-binding cell adhesion molecule (OPCML). Papyrus Therapeutics is based in Oxford, UK. The company's expertise in this target is based on years of research and multiple publications by the company's co-founder and chief scientific adviser, Professor Hani Gabra. The company was founded by Paul Blake and Hani Gabra, and Paul Blake has been the CEO since incorporation. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
| Gründer | - | - |
Karriereverlauf von Hani Gabra
Ehemalige bekannte Positionen von Hani Gabra
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BERGENBIO ASA | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2019 | - |
| Corporate Officer/Principal | 06.08.2021 | 01.05.2022 | |
| ASTRAZENECA PLC | Corporate Officer/Principal | - | - |
Statistik
International
| Vereinigtes Königreich | 3 |
| Norwegen | 2 |
| Vereinigte Staaten | 2 |
Operativ
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BERGENBIO ASA | Health Technology |
| ASTRAZENECA PLC | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Papyrus Therapeutics, Inc.
Papyrus Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Papyrus Therapeutics, Inc. is a preclinical stage biopharma American company that focuses on developing cancer therapeutics based on a novel target, opioid-binding cell adhesion molecule (OPCML). Papyrus Therapeutics is based in Oxford, UK. The company's expertise in this target is based on years of research and multiple publications by the company's co-founder and chief scientific adviser, Professor Hani Gabra. The company was founded by Paul Blake and Hani Gabra, and Paul Blake has been the CEO since incorporation. | Commercial Services |
- Börse
- Insiders
- Hani Gabra
- Erfahrung
